Prognostic value of extracellular vesicles in colorectal cancer: a systematic review and meta-analysis.

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2025-09-01 Epub Date: 2025-04-09 DOI:10.1007/s12094-025-03915-z

Haodong Zhang, Bohan Wu, Tingting Zhou, Liaoqiong Fang

{"title":"Prognostic value of extracellular vesicles in colorectal cancer: a systematic review and meta-analysis.","authors":"Haodong Zhang, Bohan Wu, Tingting Zhou, Liaoqiong Fang","doi":"10.1007/s12094-025-03915-z","DOIUrl":null,"url":null,"abstract":"Objective: Extracellular vesicles (EVs) are prognostic factors in colorectal cancer (CRC). This study aims to evaluate the prognostic value of EVs CRC.Methods: Clinical studies that directly investigated the association between EVs in different kinds of body fluids of CRC patients and patient prognosis were included by searching the PubMed, Web of Science, ClinicalTrials, and CENTRAL databases. The associations between single biomarkers, molecular panels, and EVs count with overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) were analyzed. Heterogeneity was assessed using the I2 statistic, with a random-effects model applied when I2 > 30% and a fixed-effects model when I2 ≤ 30%.Results: A total of 56 studies involving 5,985 patients were included. All included studies detected EVs in blood. Univariate analysis revealed an association between EVs single-biomarkers and OS (pHR = 2.07, 95% CI: 1.73-2.73) and DFS (pHR = 2.20, 95% CI: 1.46-2.79). Additionally, univariate analysis revealed an association between molecular-panels in EVs and OS (pHR = 3.67, 95% CI: 2.51-5.36) and RFS (pHR = 3.97, 95% CI: 1.57-10.08). Moreover, an association was observed between a EVs count and OS (pHR = 1.87, 95% CI: 1.40-2.49). On the basis of the results of the meta-regression and subgroup analyses, the subgroups of EVs and the disease stage of CRC patients are key factors contributing to the heterogeneity in the associations between EVs single-biomarkers and OS.Conclusion: This study provides compelling evidence that EVs from blood hold prognostic value in CRC.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3687-3700"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-03915-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Extracellular vesicles (EVs) are prognostic factors in colorectal cancer (CRC). This study aims to evaluate the prognostic value of EVs CRC.

Methods: Clinical studies that directly investigated the association between EVs in different kinds of body fluids of CRC patients and patient prognosis were included by searching the PubMed, Web of Science, ClinicalTrials, and CENTRAL databases. The associations between single biomarkers, molecular panels, and EVs count with overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) were analyzed. Heterogeneity was assessed using the I² statistic, with a random-effects model applied when I² > 30% and a fixed-effects model when I² ≤ 30%.

Results: A total of 56 studies involving 5,985 patients were included. All included studies detected EVs in blood. Univariate analysis revealed an association between EVs single-biomarkers and OS (pHR = 2.07, 95% CI: 1.73-2.73) and DFS (pHR = 2.20, 95% CI: 1.46-2.79). Additionally, univariate analysis revealed an association between molecular-panels in EVs and OS (pHR = 3.67, 95% CI: 2.51-5.36) and RFS (pHR = 3.97, 95% CI: 1.57-10.08). Moreover, an association was observed between a EVs count and OS (pHR = 1.87, 95% CI: 1.40-2.49). On the basis of the results of the meta-regression and subgroup analyses, the subgroups of EVs and the disease stage of CRC patients are key factors contributing to the heterogeneity in the associations between EVs single-biomarkers and OS.

Conclusion: This study provides compelling evidence that EVs from blood hold prognostic value in CRC.

查看原文本刊更多论文

结直肠癌细胞外囊泡的预后价值：一项系统综述和荟萃分析。

目的：细胞外囊泡（EVs）是影响结直肠癌预后的重要因素。本研究旨在评价电动汽车结直肠癌的预后价值。方法：通过检索PubMed、Web of Science、ClinicalTrials和CENTRAL数据库，纳入直接探讨结直肠癌患者不同体液中EVs与患者预后关系的临床研究。分析单个生物标志物、分子面板和ev计数与总生存期（OS）、无病生存期（DFS）和无复发生存期（RFS）之间的关系。采用I2统计量评估异质性，I2≤30%时采用随机效应模型，I2≤30%时采用固定效应模型。结果：共纳入56项研究，涉及5985例患者。所有纳入的研究都在血液中检测到ev。单因素分析显示ev单一生物标志物与OS （pHR = 2.07, 95% CI: 1.73-2.73）和DFS （pHR = 2.20, 95% CI: 1.46-2.79）存在相关性。此外，单变量分析显示ev中的分子面板与OS （pHR = 3.67, 95% CI: 2.51-5.36）和RFS （pHR = 3.97, 95% CI: 1.57-10.08）之间存在关联。此外，EVs计数与OS之间存在关联（pHR = 1.87, 95% CI: 1.40-2.49）。meta回归和亚组分析结果显示，EVs的亚组和CRC患者的疾病分期是导致EVs单一生物标志物与OS相关性异质性的关键因素。结论：本研究提供了令人信服的证据，证明来自血液的ev在结直肠癌中具有预后价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.